Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The first patient has now been randomised to the SCALOP-2 trial, a multi-centre randomised study of induction chemotherapy followed by capecitabine (+/- nelfinavir) with high or standard dose radiotherapy for locally advanced non-metastatic pancreatic cancer.

Similar stories

IMP-MEL Trial given Green Light to open

OCTRU have now given Green Light approval for IMP MEL to open. This is a phase 1 first-in-human dose finding/randomised phase 2 study of IMM60 and pembrolizumab in advanced melanoma and NSCLC.

WISE opens to recruitment

The WISE Study - Wrist Injury Strengthening Exercise: a randomised multicentre feasibility study of resistance exercise versus usual care for optimising function after distal radius fracture in adults aged 50 years or over has now received OCTRU Green Light approval and has opened to recruitment.

International Clinical Trials Day

Researchers across the world celebrate International Clinical Trials Day today. We have produced a short animation this year to mark the occasion...

Clinical trial finds Azithromycin has no benefit against COVID-19

A clinical trial by University of Oxford researchers has confirmed that the antibiotic azithromycin has no clinical benefit in people with moderate COVID-19.

Study reveals the three most important aspects of care for hip fractures

Older patients with hip fractures recover better if they receive treatment under the supervision of both a surgeon and a specialist in elderly care; are checked to avoid future falls; and are assessed for memory problems.